<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627276</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000581419</org_study_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>OHSU-3872</secondary_id>
    <secondary_id>OHSU-CTRC-1037</secondary_id>
    <secondary_id>NCI-2013-00768</secondary_id>
    <nct_id>NCT00627276</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia</brief_title>
  <official_title>Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One&#xD;
      type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect&#xD;
      the growth of abnormal breast cells.&#xD;
&#xD;
      PURPOSE: This randomized pilot trial is studying how well omega-3 fatty acids work in&#xD;
      treating women with newly diagnosed ductal carcinoma in situ and/or atypical ductal&#xD;
      hyperplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the effect of omega-3 fatty acids on markers of breast cancer progression&#xD;
           in women with newly diagnosed ductal carcinoma in situ and/or atypical ductal&#xD;
           hyperplasia.&#xD;
&#xD;
        -  To determine the effect of omega-3 fatty acids on specific targets identified by&#xD;
           microarray in breast cancer cells and in primary cultures from benign and malignant&#xD;
           breast tissue biopsies.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8&#xD;
           weeks.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo olive oil capsules 3 times daily for up to 8&#xD;
           weeks.&#xD;
&#xD;
      Patients complete questionnaires at baseline, weekly during study treatment, at the&#xD;
      completion of study treatment, and then at 30 days after completion of study treatment. These&#xD;
      questionnaires include the Fish Oil Adverse Event Questionnaire, the Diet and Family History&#xD;
      Questionnaire, the Changes to Diet and Medications Questionnaire, and the Post-Intervention&#xD;
      Questionnaire.&#xD;
&#xD;
      Patients undergo blood, urine, nipple aspirate, and tissue sample collection at baseline and&#xD;
      after completion of study treatment for translational research studies. Blood samples are&#xD;
      analyzed for genetic markers for breast cancer risk and progression by microarray analysis&#xD;
      and red blood cell (RBC) fatty acids. Nipple aspirate samples are analyzed for fatty acids to&#xD;
      determine the extent to which omega-3 fatty acid supplementation alters the fatty acid&#xD;
      profile of breast tissue. Tissue samples are analyzed for the presence of ductal carcinoma in&#xD;
      situ and/or atypical ductal hyperplasia or invasive cancer. Leftover blood, urine, nipple&#xD;
      aspirate, and tissue samples are stored for future research studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of omega-3 fatty acids on markers of breast cancer progression</measure>
    <time_frame>minimum 2 weeks, maximum 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega-3 fatty acid</intervention_name>
    <description>Oral, 3 times daily</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral, 3 times daily</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy confirmed diagnosis of any of the following:&#xD;
&#xD;
               -  Ductal carcinoma in situ (DCIS) and/or atypical ductal hyperplasia (ADH)&#xD;
&#xD;
               -  DCIS with a component of invasive carcinoma&#xD;
&#xD;
               -  ADH with a component of invasive carcinoma&#xD;
&#xD;
               -  DCIS and ADH with a component of invasive carcinoma&#xD;
&#xD;
          -  Newly diagnosed disease&#xD;
&#xD;
          -  No pure invasive breast cancer on biopsy without a component of DCIS or ADH&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Speaks English or Spanish&#xD;
&#xD;
          -  No allergy to fish oil or olive oil&#xD;
&#xD;
          -  No condition that, in the opinion of the study clinician, would make participation in&#xD;
             the study harmful to the patient&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation&#xD;
&#xD;
          -  No concurrent use of fish oil &gt; 1 g/day&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jackilen Shannon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Epic Imaging</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>February 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2008</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jackie Shannon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>atypical ductal breast hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

